Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas

To uncover mechanisms of nonalcoholic steatohepatitis (NASH) associated hepatocarcinogenesis, we compared the proteomes of human NASH-associated liver biopsies, resected hepatocellular carcinomas (HCCs) and HCCs of HCV+ patients with normal liver tissue of patients with gastrointestinal tumor metastasis, in formalin-fixed paraffin-embedded samples obtained after surgery in our hospital during the period from 2006 to 2011. In addition, proteome analysis of liver tumors in male STAM NASH-model mice was performed. Similar changes in the proteome spectrum such as overexpression of enzymes involved in lipid, cholesterol and bile acid biosynthesis and examples associated with suppression of fatty acid oxidation and catabolism, alcohol metabolism, mitochondrial function as well as low expression levels of cytokeratins 8 and 18 were observed in both human NASH biopsies and NASH HCCs, but not HCV+ HCCs. Alterations in downstream protein expression pointed to significant activation of transforming growth factor β, SMAD family member 3, β-catenin, Nrf2, SREBP-LXRα and nuclear receptor-interacting protein 1 (NRIP1), and inhibition of PPARs and p53 in human NASH biopsies and/or HCCs, suggesting their involvement in accumulation of lipids, development of fibrosis, oxidative stress, cell proliferation and suppression of apoptosis in NASH hepatocarcinogenesis. In STAM mice, PPARs inhibition was not obvious, while expression of cytokeratins 8 and 18 was elevated, indicative of essential differences between human and mouse NASH pathogenesis.

[1]  O. Yokosuka,et al.  Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. , 2015, World journal of gastroenterology.

[2]  Takafumi Suzuki,et al.  Molecular basis of the Keap1-Nrf2 system. , 2015, Free radical biology & medicine.

[3]  Aijaz Ahmed,et al.  Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  N. Chavez-Tapia,et al.  The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. , 2015, Annals of hepatology.

[5]  A. Ascensão,et al.  Endoplasmic Reticulum Stress Response in Non-alcoholic Steatohepatitis: The Possible Role of Physical Exercise. , 2015, Metabolism: clinical and experimental.

[6]  E. van Marck,et al.  PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. , 2015, Journal of hepatology.

[7]  T. Duarte,et al.  The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism , 2015, BioMed research international.

[8]  T. Okanoue,et al.  Influence of lifestyle‐related diseases and age on the development and progression of non‐alcoholic fatty liver disease , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  M. Ziol,et al.  Keratins 8 and 18 are type II acute‐phase responsive genes overexpressed in human liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[10]  J. Moreaux,et al.  Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia , 2015, Journal of Hematology & Oncology.

[11]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[12]  M. Zannini,et al.  NRIP1/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome. , 2014, Human molecular genetics.

[13]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[14]  Miran Kim,et al.  Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.

[15]  Y. Mitsuishi,et al.  The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism , 2012, Front. Oncol..

[16]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  S. Harrison,et al.  Hepatitis C virus infection and nonalcoholic steatohepatitis. , 2012, Gastroenterology & hepatology.

[18]  E. Chu,et al.  PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice , 2012, British Journal of Cancer.

[19]  C. Brenner,et al.  Non-alcoholic steatohepatitis: new insights from OMICS studies. , 2012, Current pharmaceutical biotechnology.

[20]  D. Torres,et al.  Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma: Fertile Soil , 2012, Seminars in Liver Disease.

[21]  M. Yeh,et al.  Peroxisome proliferator‐activated receptor‐α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non‐alcoholic steatohepatitis , 2012, Journal of gastroenterology and hepatology.

[22]  Yinghua Shen,et al.  [Effects of telmisartan on nonalcoholic steatohepatitis rat model by activating peroxisome proliferator-activated receptor r]. , 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[23]  J. Muntané,et al.  Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)* , 2011, The Journal of Biological Chemistry.

[24]  D. Haro,et al.  Human HMGCS2 Regulates Mitochondrial Fatty Acid Oxidation and FGF21 Expression in HepG2 Cell Line* , 2011, The Journal of Biological Chemistry.

[25]  S. Ballinger,et al.  Role of reactive oxygen species in injury-induced insulin resistance. , 2011, Molecular endocrinology.

[26]  F. Foufelle,et al.  Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c , 2010, Diabetes, obesity & metabolism.

[27]  R. Xavier,et al.  Wnt signaling regulates mitochondrial physiology and insulin sensitivity. , 2010, Genes & development.

[28]  H. Ford,et al.  Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression , 2010, Journal of Mammary Gland Biology and Neoplasia.

[29]  A. Cheng,et al.  PPARγ is essential for protection against nonalcoholic steatohepatitis , 2010, Gene Therapy.

[30]  J. Hardwick,et al.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease , 2010, PPAR research.

[31]  Mihee M. Kim,et al.  The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 , 2010, Nature Cell Biology.

[32]  J. Dufour,et al.  Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. , 2010, Clinical science.

[33]  M. Pagano,et al.  Wnt signaling in mitosis. , 2009, Developmental cell.

[34]  H. Yoshiji,et al.  Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. , 2009, World journal of gastroenterology.

[35]  R. Kulkarni,et al.  Wnt signaling: relevance to β-cell biology and diabetes , 2008, Trends in Endocrinology & Metabolism.

[36]  N. Kiyosawa,et al.  Species-specific regulation of PXR/CAR/ER-target genes in the mouse and rat liver elicited by o, p'-DDT , 2008, BMC Genomics.

[37]  Y. Miyamoto,et al.  Generation and characterization of a monoclonal antibody against NPI-1 subfamily of importin alpha. , 2008, Hybridoma.

[38]  J. Hardwick Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.

[39]  R. Nusse,et al.  Wnt signaling and stem cell control , 2008, Cell Research.

[40]  Y. Komiya,et al.  Wnt signal transduction pathways , 2008, Organogenesis.

[41]  R. Nusse,et al.  Wnt/β-Catenin Signaling in Murine Hepatic Transit Amplifying Progenitor Cells , 2007 .

[42]  Yutaka Matsuyama,et al.  Staging of Hepatocellular Carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan , 2007, Annals of surgery.

[43]  José L Sevilla,et al.  Identification of a gene-pathway associated with non-alcoholic steatohepatitis. , 2007, Journal of hepatology.

[44]  Hideki Yamamoto,et al.  Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. , 2007, The Biochemical journal.

[45]  C. McClain,et al.  Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. , 2007, The Journal of nutritional biochemistry.

[46]  Lisa M Yerian,et al.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.

[47]  H. Stefánsson,et al.  Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.

[48]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.

[49]  J. Féher,et al.  [Treatment of non-alcoholic steatohepatitis]. , 2004, Orvosi hetilap.

[50]  K. Okita,et al.  Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. , 2004, Biochemical and biophysical research communications.

[51]  G. Gores,et al.  Apoptosis: The nexus of liver injury and fibrosis , 2004, Hepatology.

[52]  S. Kliewer,et al.  Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.

[53]  L. Ellis,et al.  Simplified staging for hepatocellular carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Fukushima,et al.  Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. , 2002, Carcinogenesis.

[55]  J. Chiang,et al.  Transcriptional Regulation of the Human Sterol 12α-Hydroxylase Gene (CYP8B1) , 2001, The Journal of Biological Chemistry.

[56]  R. Nusse,et al.  Wnt signaling: a common theme in animal development. , 1997, Genes & development.

[57]  Roel Nusse,et al.  Wnt genes , 1992, Cell.

[58]  C. Mantzoros,et al.  Leptin in nonalcoholic fatty liver disease: a narrative review. , 2015, Metabolism: clinical and experimental.

[59]  H. Baba,et al.  Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-β signaling. , 2013, Oncology letters.

[60]  S. Fukushima,et al.  Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[61]  J. Corton,et al.  Characterization of peroxisome proliferator-activated receptor alpha--independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[62]  Xi He,et al.  Wnt/ β -catenin signaling: components, mechanisms, and diseases , 2010 .

[63]  P. Paschos,et al.  Non alcoholic fatty liver disease and metabolic syndrome. , 2009, Hippokratia.

[64]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.